METTL14 Protein
<div class="infobox infobox-protein">
<div class="infobox-header">METTL14 Protein (m6A Methyltransferase Subunit)</div>
Overview
METTL14 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@yao2022]
<div class="infobox-row"><strong>Gene:</strong> [METTL14](/genes/mettl14)</div> [@chen2022]
<div class="infobox-row"><strong>UniProt:</strong> [Q9BXB1](https://www.uniprot.org/uniprot/Q9BXB1)</div> [@zhang2023]
<div class="infobox-row"><strong>PDB:</strong> 5IL1, 5K7P</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> 59.6 kDa</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Nucleus, cytosol</div>
<div class="infobox-row"><strong>Protein Family:</strong> Methyltransferase-like family, MT-A70 subfamily</div>
</div>
Structure
...METTL14 Protein
<div class="infobox infobox-protein">
<div class="infobox-header">METTL14 Protein (m6A Methyltransferase Subunit)</div>
Overview
METTL14 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@yao2022]
<div class="infobox-row"><strong>Gene:</strong> [METTL14](/genes/mettl14)</div> [@chen2022]
<div class="infobox-row"><strong>UniProt:</strong> [Q9BXB1](https://www.uniprot.org/uniprot/Q9BXB1)</div> [@zhang2023]
<div class="infobox-row"><strong>PDB:</strong> 5IL1, 5K7P</div>
<div class="infobox-row"><strong>Molecular Weight:</strong> 59.6 kDa</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Nucleus, cytosol</div>
<div class="infobox-row"><strong>Protein Family:</strong> Methyltransferase-like family, MT-A70 subfamily</div>
</div>
Structure
METTL14 (Methyltransferase Like 14) is a 456-amino acid protein that forms the substrate recognition component of the m6A methyltransferase complex. While METTL3 provides the catalytic activity, METTL14 is essential for complex formation, substrate binding, and proper cellular localization. The protein contains an N-terminal region that mediates interactions with METTL3 and WTAP, and a C-terminal methyltransferase-like domain that, despite being catalytically inactive, contributes to RNA binding. The METTL3-METTL14 heterodimer forms a saddle-shaped structure that recognizes specific RNA sequence motifs (DRACH) and positions the adenine substrate within the active site of METTL3. METTL14 contains an extended loop region that contacts the RNA substrate and contributes to substrate specificity. The protein forms a stable heterodimer with METTL3 in a 1:1 ratio, and this heterodimer further assembles with WTAP into the larger methyltransferase complex (MACOM/MAC).
Normal Function in the Nervous System
METTL14 plays essential roles in RNA metabolism in the nervous system:
- Substrate Recognition: The METTL14 subunit recognizes and binds specific mRNA sequences, determining which transcripts get methylated
- Synaptic mRNA Regulation: The complex regulates the translation of synaptic proteins through m6A modification of their mRNAs, affecting synaptic plasticity and memory formation
- Neuronal Differentiation: m6A modification regulates the timing of neuronal differentiation during development by controlling key transcription factor mRNAs
- Axonal Regeneration: METTL14-mediated m6A modification regulates the regenerative capacity of [neurons](/entities/neurons) after injury
- Glial Function: Important for oligodendrocyte precursor cell differentiation and myelin formation
METTL14 is expressed throughout the brain, with high expression in the [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and cerebellum. Like METTL3, its expression is dynamically regulated during development and in response to neural activity.
Role in Neurodegeneration
Alzheimer's Disease
METTL14 dysfunction contributes to Alzheimer's disease pathogenesis through altered m6A modification of key AD-related transcripts. Studies show reduced METTL14 expression in AD brains, leading to decreased m6A levels on [amyloid precursor protein](/entities/app-protein) (APP) and [tau](/proteins/tau) mRNAs. This dysregulation affects APP processing and tau phosphorylation, contributing to amyloid and tau pathology. The m6A reader YTHDF1, which promotes translation, shows altered expression in AD, creating a complex dysregulation of m6A-mediated translation control.
Parkinson's Disease
In Parkinson's disease, METTL14 plays a role in regulating the translation of mitochondrial function and [autophagy](/entities/autophagy)-related transcripts. [Alpha-synuclein](/proteins/alpha-synuclein) mRNA is modified by m6A, and METTL14 activity affects its translation efficiency. Dysregulated m6A methylation contributes to mitochondrial dysfunction in dopaminergic neurons, a key feature of PD pathogenesis.
Stroke and Ischemia
Following cerebral ischemia, METTL14 expression is altered, affecting the m6A modification of stress response genes. The m6A pathway regulates neuronal survival after ischemic injury, with METTL14 knockdown protecting against ischemia-reperfusion injury in some models. This suggests potential therapeutic applications in stroke treatment.
Neurodevelopmental Disorders
Loss-of-function variants in METTL14 cause neurodevelopmental disorders with intellectual disability and speech impairment, highlighting the essential role of m6A methylation in human brain development. The phenotype overlaps with METTL3-related disorders, confirming the importance of the intact methyltransferase complex.
Therapeutic Targeting
Therapeutic modulation of METTL14 is being explored:
- Small Molecule Modulators: Compounds that enhance METTL14-METTL3 interaction could boost m6A modification of neuroprotective transcripts
- RNA-Based Therapeutics: m6A-modified mRNA therapeutics could bypass defective methylation to express therapeutic proteins
- Reader Protein Modulators: Targeting downstream reader proteins may be more tractable than targeting the methyltransferase complex
- Gene Expression Modulators: AAV vectors expressing METTL14 could restore m6A homeostasis in disease states
Pathway & Interaction Diagram
Interactive diagram showing METTL14's key relationships in the SciDEX knowledge graph (5 connections shown).
Mermaid diagram (expand to render)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Zhou J, et al, METTL14 in the regulation of neurodevelopment and neurodegeneration (2023)](https://doi.org/10.1007/s10571-022-01299-0)
[Weng YL, et al, Epitranscriptomic m6A regulation of axon regeneration in the adult mammalian nervous system (2018)](https://doi.org/10.1016/j.neuron.2017.12.036)
[Yao Y, et al, METTL14 deficiency reduces amyloid-beta generation through regulating APP mRNA splicing (2022)](https://doi.org/10.1186/s13195-022-01103-7)
[Chen X, et al, N6-methyladenosine regulates RNA metabolism in neurodegeneration (2022)](https://doi.org/10.1016/j.tins.2022.03.005)
[Zhang Z, et al, METTL14-mediated m6A modification in neurological diseases (2023)](https://doi.org/10.3389/fnmol.2023.1184621)